{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:24:59Z","timestamp":1794360299044,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Institutes of Health","award":["R01HL62150-32"],"award-info":[{"award-number":["R01HL62150-32"]}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R21AI200456-01"],"award-info":[{"award-number":["1R21AI200456-01"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"DOI":"10.1007\/s40268-026-00551-y","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:55:57Z","timestamp":1790391357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-Fungal and Toxicology Assessment of ISFP10, an Inhibitor of Fungal Phosphoglucomutase (PGM)"],"prefix":"10.1007","author":[{"given":"Madeline R.","family":"Pellegrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bindzus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0364-3311","authenticated-orcid":false,"given":"Theodore J.","family":"Kottom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Ayyalasomayajula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad C.","family":"Achilonu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhee S.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Limper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"8","key":"551_CR1","doi-asserted-by":"publisher","first-page":"869","DOI":"10.4155\/fmc-2018-0465","volume":"11","author":"S Hasim","year":"2019","unstructured":"Hasim S, Coleman JJ. Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents. Future Med Chem. 2019;11(8):869\u201383.","journal-title":"Future Med Chem"},{"key":"551_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00756-23","volume":"68","author":"T Kottom","year":"2024","unstructured":"Kottom T, Carmona E, Limper A. Characterization of the Pneumocystis jirovecii and Pneumocystis murina phosphoglucomutases (Pgm2s): a potential target for Pneumocystis therapy. Antimicrob Agents Chemother. 2024;68:e0075623.","journal-title":"Antimicrob Agents Chemother"},{"key":"551_CR3","doi-asserted-by":"crossref","unstructured":"Yan KZ et al. Genetic validation of phosphoglucomutase as a viable therapeutic target in invasive aspergillosis. J Biol Chem. 2022;298(6):102003.","DOI":"10.1016\/j.jbc.2022.102003"},{"issue":"11","key":"551_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab444","volume":"8","author":"NP Wiederhold","year":"2021","unstructured":"Wiederhold NP. Antifungal susceptibility testing: a primer for clinicians. Open Forum Infect Dis. 2021;8(11):ofab444.","journal-title":"Open Forum Infect Dis"},{"key":"551_CR5","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi","author":"Clinical and L.S. Institute","year":"2017","unstructured":"Clinical and L.S. Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. e. rd. Wayne: Clinical and Laboratory Standards Institute; 2017.","edition":"e. rd"},{"key":"551_CR6","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Clinical and L.S. Institute","year":"2017","unstructured":"Clinical and L.S. Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. e. th. Wayne: Clinical and Laboratory Standards Institute; 2017.","edition":"e. th"},{"issue":"12","key":"551_CR7","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1128\/JCM.39.12.4309-4315.2001","volume":"39","author":"M Tamura","year":"2001","unstructured":"Tamura M, et al. Molecular characterization of new clinical isolates of Candida albicans and C. dubliniensis in Japan: analysis reveals a new genotype of C. albicans with group I intron. J Clin Microbiol. 2001;39(12):4309\u201315.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"551_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/mmi.14488","volume":"113","author":"Z Xu","year":"2020","unstructured":"Xu Z, et al. De novo genome assembly of Candida glabrata reveals cell wall protein complement and structure of dispersed tandem repeat arrays. Mol Microbiol. 2020;113(6):1209\u201324.","journal-title":"Mol Microbiol"},{"issue":"4","key":"551_CR9","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1128\/IAI.01497-07","volume":"76","author":"MM Maidan","year":"2008","unstructured":"Maidan MM, et al. Combined inactivation of the Candida albicans GPR1 and TPS2 genes results in avirulence in a mouse model for systemic infection. Infect Immun. 2008;76(4):1686\u201394.","journal-title":"Infect Immun"},{"issue":"3","key":"551_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40268-024-00483-5","volume":"24","author":"TJ Kottom","year":"2024","unstructured":"Kottom TJ, et al. Preclinical and toxicology assessment of ALW-II-41-27, an inhibitor of the Eph receptor A2 (EphA2). Drugs R D. 2024;24(3):425\u201334.","journal-title":"Drugs R D"},{"issue":"4","key":"551_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1165\/rcmb.2022-0339OC","volume":"69","author":"M Choudhury","year":"2023","unstructured":"Choudhury M, et al. Targeting pulmonary fibrosis by SLC1A5-dependent glutamine transport blockade. Am J Respir Cell Mol Biol. 2023;69(4):441\u201355.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"551_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40268-022-00389-0","volume":"22","author":"TJ Kottom","year":"2022","unstructured":"Kottom TJ, et al. Preclinical and toxicology studies of BRD5529, a selective inhibitor of CARD9. Drugs R D. 2022;22(2):165\u201373.","journal-title":"Drugs R D"},{"issue":"2","key":"551_CR13","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1096\/fj.201902354R","volume":"34","author":"JH Kang","year":"2020","unstructured":"Kang JH, et al. Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD-L1 into extracellular vesicles. FASEB J. 2020;34(2):2213\u201326.","journal-title":"FASEB J"},{"issue":"11","key":"551_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003772","volume":"3","author":"C Mazzaccara","year":"2008","unstructured":"Mazzaccara C, et al. Age-related reference intervals of the main biochemical and hematological parameters in C57BL\/6J, 129SV\/EV and C3H\/HeJ mouse strains. PLoS ONE. 2008;3(11):e3772.","journal-title":"PLoS ONE"},{"issue":"Pt 1","key":"551_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1099\/jmm.0.045054-0","volume":"62","author":"JCO Sardi","year":"2013","unstructured":"Sardi JCO, et al. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62(Pt 1):10\u201324.","journal-title":"J Med Microbiol"},{"issue":"2","key":"551_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrmicro2711","volume":"10","author":"NA Gow","year":"2011","unstructured":"Gow NA, et al. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol. 2011;10(2):112\u201322.","journal-title":"Nat Rev Microbiol"},{"issue":"15","key":"551_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMra1315399","volume":"373","author":"BJ Kullberg","year":"2015","unstructured":"Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373(15):1445\u201356.","journal-title":"N Engl J Med"},{"issue":"9","key":"551_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/cid\/cit006","volume":"56","author":"CJ Clancy","year":"2013","unstructured":"Clancy CJ, Nguyen MH. Finding the \u201cmissing 50%\u201d of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284\u201392.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"551_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219.","journal-title":"Crit Care"},{"issue":"4","key":"551_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","volume":"39","author":"DH Kett","year":"2011","unstructured":"Kett DH, et al. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39(4):665\u201370.","journal-title":"Crit Care Med"},{"issue":"10","key":"551_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","volume":"25","author":"P Koehler","year":"2019","unstructured":"Koehler P, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200\u201312.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"551_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1439-0507.2011.02044.x","volume":"55","author":"AM Tortorano","year":"2012","unstructured":"Tortorano AM, et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006\u20132008). Mycoses. 2012;55(1):73\u20139.","journal-title":"Mycoses"},{"issue":"3","key":"551_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s15010-013-0432-0","volume":"41","author":"MT Montagna","year":"2013","unstructured":"Montagna MT, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA project). Infection. 2013;41(3):645\u201353.","journal-title":"Infection"},{"issue":"1","key":"551_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jinf.2017.03.011","volume":"75","author":"O Baldesi","year":"2017","unstructured":"Baldesi O, et al. ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004\u20132013 - a study from the REA-RAISIN network. J Infect. 2017;75(1):59\u201367.","journal-title":"J Infect"},{"issue":"3","key":"551_CR25","doi-asserted-by":"publisher","DOI":"10.5867\/medwave.2020.03.7867","volume":"20","author":"G Rada","year":"2020","unstructured":"Rada G, et al. Evidence synthesis relevant to COVID-19: a protocol for multiple systematic reviews and overviews of systematic reviews. Medwave. 2020;20(3):e7868.","journal-title":"Medwave"},{"key":"551_CR26","volume":"7","author":"SG Whaley","year":"2016","unstructured":"Whaley SG, et al. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol. 2016;7:2173.","journal-title":"Front Microbiol"},{"issue":"7","key":"551_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cmi.2019.03.028","volume":"25","author":"KE Pristov","year":"2019","unstructured":"Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25(7):792\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"551_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcsw.2024.100123","volume":"11","author":"TJ Kottom","year":"2024","unstructured":"Kottom TJ, et al. Metabolic modulation: Pneumocystis phosphoglucomutase is a target influencing host recognition. Cell Surf. 2024;11:100123.","journal-title":"Cell Surf"},{"issue":"6","key":"551_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102003","volume":"298","author":"K Yan","year":"2022","unstructured":"Yan K, et al. Genetic validation of Aspergillus fumigatus phosphoglucomutase as a viable therapeutic target in invasive aspergillosis. J Biol Chem. 2022;298(6):102003.","journal-title":"J Biol Chem"},{"key":"551_CR30","doi-asserted-by":"crossref","unstructured":"Kottom TJ and Limper AH. The maximum-tolerated dose and pharmacokinetics of ISFP10 a novel inhibitor of fungal phosphoglucomutase (PGM). bioRxiv 2025.","DOI":"10.1101\/2025.06.17.660114"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-026-00551-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-026-00551-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:02:36Z","timestamp":1790449356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-026-00551-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":30,"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s40268-026-00551-y","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by the Mayo Foundation; the Walter and Leonore Annenberg Foundation, and NIH grants R01HL62150-33 and R21AI200456-01 to A.H.L.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC) approved protocol A00007622-24 on 4\/1\/2023.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.R.P., M.B., T.J.K., S.A., C.C.A., E.S.Y., and A.H.L. made substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data. M.R.P. and M.B. are co-first authors. All authors approved the version to be published.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}